NCT06810960 · RECRUITING
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
This is a postmarketing surveillance study in South Korea tracking real-world safety of lecanemab (Leqembi), an already-approved anti-amyloid antibody drug for Alzheimer's disease. Researchers are watching for serious brain imaging abnormalities — swelling and microbleeds known as ARIA — and larger brain bleeds in patients already prescribed the drug by their doctors. No phase designation applies because this is observational, not an experimental trial.
You may qualify if
- Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
- The clinical decision to treat with LEQEMBI has already been made
- Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.
You're excluded if
- Currently participating in an interventional clinical study
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-21